United States Platinum Based Cancer Drug Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The global platinum-based cancer drug market reached USD 1.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1.8 billion by 2030. The global platinum-based cancer drug market is expected to exhibit a CAGR of 3.2% during the forecast period (2023-2030).

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Novocure's Optune Lua® received approval in the U.S. for use in combination with PD-1/PD-L1 inhibitors for advanced non-small cell lung cancer (NSCLC) patients who have progressed after platinum-based chemotherapy. This approval marks a significant advancement in treatment options for this patient group.

✅ In August 2025, Genmab received FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in advanced endometrial cancer. This designation underscores the potential of Rina-S® to offer a new treatment avenue for patients with this challenging cancer.

✅ In July 2025, Corcept Therapeutics submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator, aimed at treating platinum-resistant ovarian cancer. If approved, relacorilant could provide a novel therapeutic option for patients with this condition.

Japan: Recent Industry Developments

✅ In September 2025, Japan's Ministry of Health, Labour and Welfare approved Novocure's Optune Lua® for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable, advanced/recurrent NSCLC who have progressed after platinum-based chemotherapy. This approval expands treatment options for Japanese patients with advanced lung cancer.

✅ In August 2025, Daiichi Sankyo's Datroway received approval in Japan for the treatment of EGFR-mutated NSCLC. This approval provides Japanese patients with a new targeted therapy option for this specific genetic mutation.

✅ In March 2025, Daiichi Sankyo's Raludotatug Deruxtecan (R-DXd) was granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of platinum-resistant ovarian cancer. This designation highlights the potential of R-DXd to address unmet medical needs in this patient population.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/platinum-based-cancer-drug-market?sb

Recent Mergers and acquisitions :

United States: Recent M&A Activity
✅ In October 2025, BioCryst Pharmaceuticals announced its acquisition of Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million. This strategic move aims to reinforce BioCryst's rare diseases portfolio, bringing Astria's lead drug candidate, navenibart, into BioCryst's pipeline. Navenibart is an injectable therapy in late-stage trials aiming to prevent hereditary angioedema (HAE), with data expected in early 2027.

✅ In August 2025, Bayer entered into a deal worth up to $1.3 billion with U.S.-based Kumquat Biosciences to develop a potential new cancer drug. The agreement focuses on a KRAS G12D inhibitor, a targeted therapy candidate with no effective treatments currently available for certain KRAS mutations, which are involved in about 25% of human cancers. Kumquat will lead the initial Phase Ia clinical trials, while Bayer will handle later-stage development and commercialization.

✅ In March 2025, AstraZeneca acquired the Belgian biotech company EsoBiotec for up to $1 billion. EsoBiotec specializes in in-vivo CAR-T cell therapies, designed to empower the immune system to attack cancer and treat autoimmune diseases through simple injections rather than the traditional lengthy process. This acquisition is part of AstraZeneca's ongoing expansion and investment in innovative treatments.

Japan: Latest M&A Activity
✅ In February 2025, Bain Capital acquired Mitsubishi Tanabe Pharma for ¥510 billion ($3.4 billion). The deal aims to enhance Mitsubishi Tanabe's oncology pipeline, including treatments for lung and gastrointestinal cancers. This acquisition is part of a broader trend of private equity buyouts in Japan amid pressure to enhance corporate and shareholder value.

✅ In May 2025, Shionogi & Co., Ltd. announced the acquisition of Torii Pharmaceutical Co., Ltd., a subsidiary of Japan Tobacco Inc., for approximately ¥150 billion ($1.05 billion). This acquisition aims to strengthen Shionogi's oncology portfolio, including treatments for platinum-resistant cancers.

Key Players:

=> Pfizer, Inc., Accord Healthcare, Sanofi, Sun Pharmaceutical Industries Ltd., MorphoSys AG, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Novartis AG and Merck & Co., Inc. among others.

Growth Forecast Projected:

The Global Platinum Based Cancer Drug Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Platinum Based Cancer Drug Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=platinum-based-cancer-drug-market

Key Segments:

➥ By Drug Type: Cisplatin, Oxaliplatin, Carboplatin, Others

➥ By Application: Colorectal Cancer, Lung Cancer, Breast Cancer, Others

➥ By End-User: Hospitals, Specialty Clinics, Others

Regional Analysis for Platinum Based Cancer Drug Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Platinum Based Cancer Drug producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Platinum Based Cancer Drug revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/platinum-based-cancer-drug-market?sb

FAQ

What is the current size of the Platinum Based Cancer Drug Market?

A: In 2022, the Platinum Based Cancer Drug Market was valued at USD 1.4 billion , reflecting its strong industry presence.

Q2: How large is the Platinum Based Cancer Drug Market expected to be by 2030?

A: By 2030, industry forecasts suggest the Platinum Based Cancer Drug Market will grow to around USD 1.8 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Platinum Based Cancer Drug Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3.2% during the forecast period from 2023 to 2030.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.